The success of bevacizumab—which inhibits the effect of vascular endothelial growth factor by targeting neoplastic angiogenesis—in significantly prolonging progression-free survival and showing a synergistic effect on platinum agents, has shed light on tumor microenvironment-targeted therapy strategies in OvCa [93]. This evidence concerns the gene VEGFA and neoplasm.